用于低中等收入国家微针贴片潜在疫苗的识别:疫苗创新优先策略联盟的评估
微针贴片(MAPs)有望提升低中等收入国家(LMICs)的疫苗公平覆盖,但开发者需要指导哪些疫苗适合通过MAPs递送。VIPS联盟通过案头研究、外部咨询组及对监管路径、规划影响和财务可持续性的评估,从91个疫苗目标中筛选出21个适用于LMICs,最终确定11个优先疫苗目标并分为两个优先级别。
要点
- 从91个疫苗目标中筛选出21个适用于LMICs,最终确定11个VIPS优先疫苗目标并分两级。
- 优先组1包括乙肝、麻腮风/麻风腮、HPV、狂犬病、黄热病、流感(季节性和大流行)和SARS-CoV-2疫苗。
- 优先组2包括B组链球菌、脑膜炎奈瑟菌A,C,W,Y,(X)、伤寒沙门菌和肺炎链球菌疫苗。
核心结论
- 这些疫苗MAP优先目标将帮助MAP开发者、疫苗制造商、捐助方和全球卫生伙伴在投资决策和设计MAP产品组合时更好地回应国家需求。
研究设计与样本
- VIPS联盟通过案头研究汇编疫苗目标参考清单,依据给药途径、市场分布、全球/区域卫生组织现有兴趣、是否针对特定全球卫生优先事项或利益相关方议程、开发状态和潜在MAP使用场景进行筛选。
- 通过咨询外部咨询组并评估潜在监管路径、规划影响和财务可持续性,将清单进一步缩减并定义两个优先级别。
主要发现
- 从91个疫苗目标的参考清单中,识别出21个适用于LMICs的疫苗目标,进一步缩减为VIPS优先清单中的11个疫苗目标并分组。
- 优先组1包括针对乙型肝炎病毒、麻疹-风疹/麻疹-腮腺炎-风疹病毒、人乳头瘤病毒、狂犬病病毒、黄热病、流感病毒(季节性和大流行)和SARS-CoV-2的疫苗。
- 优先组2包括针对B组链球菌、脑膜炎奈瑟菌A,C,W,Y,(X)、伤寒沙门菌和肺炎链球菌的疫苗。
关键数值与推荐
- 优先组1疫苗目标:乙型肝炎病毒、麻疹-风疹/麻疹-腮腺炎-风疹病毒、人乳头瘤病毒、狂犬病病毒、黄热病、流感病毒(季节性和大流行)、SARS-CoV-2。
- 优先组2疫苗目标:B组链球菌、脑膜炎奈瑟菌A,C,W,Y,(X)、伤寒沙门菌、肺炎链球菌。
临床怎么用
- 这些疫苗MAP优先目标旨在为MAP开发者、疫苗制造商、捐助方和全球卫生伙伴的投资决策提供信息,以在设计MAP产品组合时更好地回应国家需求。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Microarray patches (MAPs) have the potential to increase equitable vaccine coverage in low- and middle-income countries (LMICs). However, MAP developers and vaccine manufacturers have identified a barrier to development of MAPs for global health applications: the need for guidance on which vaccine MAPs would be of value to LMIC immunization programs. To address this gap, the Vaccine Innovation Prioritisation Strategy (VIPS) Alliance conducted a prioritization process to identify high-priority vaccines that could be delivered via MAPs in LMICs. METHODS: We first compiled a reference list of vaccine targets through desk research, then filtered these targets based on route of administration, market distribution, existing interest from a global/regional health organization, whether the vaccine would address a specific global health priority or stakeholder agenda, development status, and potential MAP use cases. To further down-select the list, we consulted an external advisory group and evaluated the potential regulatory pathway, programmatic impact, and financial sustainability to define two priority levels. RESULTS: From a reference list of 91 vaccine targets, we identified 21 with applicability to LMICs, which were further down-selected to a VIPS priority list of 11 vaccine targets grouped by priority level. Priority group 1 included vaccines against hepatitis B virus, measles-rubella/measles-mumps-rubella viruses, human papillomavirus, rabies virus, yellow fever, influenza virus (seasonal and pandemic), and SARS-CoV-2. Priority group 2 included vaccines against Group B streptococcus, Neisseria meningitidis A,C,W,Y,(X), Salmonella Typhi, and Streptococcus pneumoniae. CONCLUSIONS: These vaccine MAP priorities will inform the investment decisions of MAP developers, vaccine manufacturers, donors, and global health partners to better respond to country needs when designing their MAP portfolios. By providing a holistic assessment of the potential drivers for and key risks of developing specific vaccine MAPs, our findings have the potential to promote MAP development activities for vaccines that are priorities for LMICs.
引用
- Frivold C, Giersing B, Amorij JP, et al. Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance. Vaccine. 2025. PMID: 40132321. doi:10.1016/j.vaccine.2025.126996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。